Decreased expression of ING2 gene and its clinicopathological significance in hepatocellular carcinoma

Cancer Letters

Volumn 261, Issue 2, 2008, Pages 183-192

  Zhang, Hua kun ^a   Pan, Ke ^a   Wang, Hui ^a   Weng, De sheng ^a   Song, Hai feng ^a   Zhou, Jun ^a   Huang, Wei ^a   Li, Jian jun ^a   Chen, Min shan ^a   Xia, Jian chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

AFP; Down regulation; Hepatocellular carcinoma; ING2; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; INHIBITOR OF GROWTH FAMILY MEMBER 2 PROTEIN; INHIBITOR PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER RISK; CELL GROWTH; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA REPAIR; DOWN REGULATION; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ING2 GENE; KAPLAN MEIER METHOD; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 39149143675     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.11.019     Document Type: Article

References (45)

1. Shimada Y., Saito A., Suzuki M., Takahashi E., and Horie M. Cloning of a novel gene (ING1L) homologous to ING1, a candidate tumor suppressor. Cytogenet. Cell Genet. 83 (1998) 232-235
2. Doyon Y., Cayrou C., Ullah M., Landry A.J., Cote V., Selleck W., et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol. Cell 21 (2006) 51-64
3. Pena P.V., Davrazou F., Shi X., Walter K.L., Verkhusha V.V., Gozani O., et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature 442 (2006) 100-103
4. Shi X., Hong T., Walter K.L., Ewalt M., Michishita E., Hung T., et al. ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature 442 (2006) 96-99
5. Gozani O., Karuman P., Jones D.R., Ivanov D., Cha J., Lugovskoy A.A., et al. The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell 114 (2003) 99-111
6. Wang Y., Wang J., and Li G. Leucine zipper-like domain is required for tumor suppressor ING2-mediated nucleotide excision repair and apoptosis. FEBS Lett. 580 (2006) 3787-3793
7. Pedeux R., Sengupta S., Shen J.C., Demidov O.N., Saito S., Onogi H., et al. ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol. Cell. Biol. 25 (2005) 6639-6648
8. Nagashima M., Shiseki M., Miura K., Hagiwara K., Linke S.P., Pedeux R., et al. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl. Acad. Sci. USA 98 (2001) 9671-9676
9. Gong W., Suzuki K., Russell M., and Riabowol K. Function of the ING family of PHD proteins in cancer. Int. J. Biochem. Cell Biol. 37 (2005) 1054-1065
10. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
11. Block T.M., Mehta A.S., Fimmel C.J., and Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 22 (2003) 5093-5107
12. Tung-Ping Poon R., Fan S.T., and Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann. Surg. 232 (2000) 10-24
13. Capocaccia R., Sant M., Berrino F., Simonetti A., Santi V., and Trevisani F. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am. J. Gastroenterol. 102 (2007) 1661-1670
14. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (2004) S27-S34
15. Thomas M.B., and Zhu A.X. Hepatocellular carcinoma: the need for progress. J. Clin. Oncol. 23 (2005) 2892-2899
16. Bluteau O., Beaudoin J.C., Pasturaud P., Belghiti J., Franco D., Bioulac-Sage P., et al. Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 21 (2002) 1225-1232
17. Bando K., Nagai H., Matsumoto S., Koyama M., Kawamura N., Onda M., et al. Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 25 (1999) 284-289
18. Lu F., Dai D.L., Martinka M., Ho V., and Li G. Nuclear ING2 expression is reduced in human cutaneous melanomas. Br. J. Cancer 95 (2006) 80-86
19. Okano T., Gemma A., Hosoya Y., Hosomi Y., Nara M., Kokubo Y., et al. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol. Rep. 15 (2006) 545-549
20. Zhu Z., Lin J., Qu J.H., Feitelson M.A., Ni C.R., Li F.M., et al. Inhibitory effect of tumor suppressor p33(ING1b) and its synergy with p53 gene in hepatocellular carcinoma. World J. Gastroenterol. 11 (2005) 1903-1909
21. Ohgi T., Masaki T., Nakai S., Morishita A., Yukimasa S., Nagai M., et al. Expression of p33(ING1) in hepatocellular carcinoma: relationships to tumour differentiation and cyclin E kinase activity. Scand. J. Gastroenterol. 37 (2002) 1440-1448
22. Mann C.D., Neal C.P., Garcea G., Manson M.M., Dennison A.R., and Berry D.P. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer 43 (2007) 979-992
23. Moradpour D., and Blum H.E. Pathogenesis of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 17 (2005) 477-483
24. Hu T.H., Huang C.C., Lin P.R., Chang H.W., Ger L.P., Lin Y.W., et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97 (2003) 1929-1940
25. Yao Y.J., Ping X.L., Zhang H., Chen F.F., Lee P.K., Ahsan H., et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 18 (1999) 3181-3185
26. Li S., Wang H., and Zhang C. Genome-wide loss of heterozygosity analyses in primary hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 80 (2000) 577-581
27. Yeh S.H., Lin M.W., Lu S.F., Wu D.C., Tsai S.F., Tsai C.Y., et al. Allelic loss of chromosome 4q21 approximately 23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein. Hepatology 40 (2004) 847-854
28. Shen D.H., Chan K.Y., Khoo U.S., Ngan H.Y., Xue W.C., Chiu P.M., et al. Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis 26 (2005) 855-863
29. Takahashi M., Ozaki T., Todo S., and Nakagawara A. Decreased expression of the candidate tumor suppressor gene ING1 is associated with poor prognosis in advanced neuroblastomas. Oncol. Rep. 12 (2004) 811-816
30. Caruso M.L., and Valentini A.M. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res. 19 (1999) 3853-3856
31. Lee K.C., Crowe A.J., and Barton M.C. p53-Mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol. Cell. Biol. 19 (1999) 1279-1288
32. Ogden S.K., Lee K.C., Wernke-Dollries K., Stratton S.A., Aronow B., and Barton M.C. p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression. J. Biol. Chem. 276 (2001) 42057-42062
33. Kataoka H., Bonnefin P., Vieyra D., Feng X., Hara Y., Miura Y., et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res. 63 (2003) 5785-5792
34. Vieyra D., Senger D.L., Toyama T., Muzik H., Brasher P.M., Johnston R.N., et al. Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. Clin. Cancer Res. 9 (2003) 5952-5961
35. Nouman G.S., Angus B., Lunec J., Crosier S., Lodge A., and Anderson J.J. Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues. Hybrid. Hybridomics 21 (2002) 1-10
36. Nouman G.S., Anderson J.J., Wood K.M., Lunec J., Hall A.G., Reid M.M., et al. Loss of nuclear expression of the p33(ING1b) inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J. Clin. Pathol. 55 (2002) 596-601
37. Qin L.X., and Tang Z.Y. The prognostic molecular markers in hepatocellular carcinoma. World J. Gastroenterol. 8 (2002) 385-392
38. Wang Y., Dai D.L., Martinka M., and Li G. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin. Cancer Res. 13 (2007) 4111-4116
39. Peng S.Y., Chen W.J., Lai P.L., Jeng Y.M., Sheu J.C., and Hsu H.C. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int. J. Cancer 112 (2004) 44-50
40. Okuda K., Tanaka M., Kanazawa N., Nagashima J., Satomura S., Kinoshita H., et al. Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein. Int. J. Oncol. 14 (1999) 265-271
41. Bressac B., Kew M., Wands J., and Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350 (1991) 429-431
42. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., and Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350 (1991) 427-428
43. Chin M.Y., Ng K.C., and Li G. The novel tumor suppressor p33ING2 enhances UVB-induced apoptosis in human melanoma cells. Exp. Cell Res. 304 (2005) 531-543
44. Meehan W.J., Samant R.S., Hopper J.E., Carrozza M.J., Shevde L.A., Workman J.L., et al. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J. Biol. Chem. 279 (2004) 1562-1569
45. Sironi E., Cerri A., Tomasini D., Sirchia S.M., Porta G., Rossella F., et al. Loss of heterozygosity on chromosome 4q32-35 in sporadic basal cell carcinomas: evidence for the involvement of p33ING2/ING1L and SAP30 genes. J. Cutan. Pathol. 31 (2004) 318-322